FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022107795> ?p ?o ?g. }

• W2022107795 endingPage "327" @default.
• W2022107795 startingPage "322" @default.
• W2022107795 abstract "BackgroundThe use of combination inhaled budesonide and formoterol as maintenance and reliever therapy significantly improves the risk and the time to exacerbations in asthma.ObjectivesTo explore the mechanisms underlying the effect of the reliever dose on exacerbations by examining the effect of combination therapy on the allergen challenge model when given after allergen exposure.MethodsIn a randomized, double-blind crossover study, single doses of budesonide/formoterol (400/12 μg), formoterol (12 μg), budesonide (400 μg), or placebo were administered during the acute bronchoconstriction response (early airway response) immediately after allergen inhalation in 15 patients with mild asthma. Allergen-induced late airway response (LAR), sputum inflammatory markers, airway hyperresponsiveness, and exhaled nitric oxide were measured.ResultsAll active treatments significantly attenuated the LAR, with budesonide/formoterol significantly better than its monocomponents (maximum FEV1 fall: placebo, [mean ± SEM] 21.2% ± 3.1%; budesonide/formoterol, 4.2% ± 1.4%; formoterol, 7.5% ± 1.7%; budesonide, 10.4% ± 1.6%). Allergen-induced change in methacholine PC20 was significantly attenuated by budesonide/formoterol, but not by its monocomponents. Sputum cell counts and exhaled nitric oxide increased significantly after all allergen challenges, with no significant attenuation by any of the treatments. Therapy with combination and formoterol alone, but not budesonide, significantly reduced the early airway response.ConclusionA single dose of budesonide/formoterol was superior to its monocomponents in attenuating the allergen-induced LAR and airway hyperresponsiveness. These effects may represent the contribution of the reliever dose to the budesonide/formoterol maintenance and reliever regimen.Clinical implicationsThe protective effect against allergic airway responses with a single reliever dose of budesonide/formoterol is predominantly related to greater functional antagonism of airway smooth muscles. The use of combination inhaled budesonide and formoterol as maintenance and reliever therapy significantly improves the risk and the time to exacerbations in asthma. To explore the mechanisms underlying the effect of the reliever dose on exacerbations by examining the effect of combination therapy on the allergen challenge model when given after allergen exposure. In a randomized, double-blind crossover study, single doses of budesonide/formoterol (400/12 μg), formoterol (12 μg), budesonide (400 μg), or placebo were administered during the acute bronchoconstriction response (early airway response) immediately after allergen inhalation in 15 patients with mild asthma. Allergen-induced late airway response (LAR), sputum inflammatory markers, airway hyperresponsiveness, and exhaled nitric oxide were measured. All active treatments significantly attenuated the LAR, with budesonide/formoterol significantly better than its monocomponents (maximum FEV1 fall: placebo, [mean ± SEM] 21.2% ± 3.1%; budesonide/formoterol, 4.2% ± 1.4%; formoterol, 7.5% ± 1.7%; budesonide, 10.4% ± 1.6%). Allergen-induced change in methacholine PC20 was significantly attenuated by budesonide/formoterol, but not by its monocomponents. Sputum cell counts and exhaled nitric oxide increased significantly after all allergen challenges, with no significant attenuation by any of the treatments. Therapy with combination and formoterol alone, but not budesonide, significantly reduced the early airway response. A single dose of budesonide/formoterol was superior to its monocomponents in attenuating the allergen-induced LAR and airway hyperresponsiveness. These effects may represent the contribution of the reliever dose to the budesonide/formoterol maintenance and reliever regimen." @default.
• W2022107795 created "2016-06-24" @default.
• W2022107795 creator A5011563899 @default.
• W2022107795 creator A5015743774 @default.
• W2022107795 creator A5018374796 @default.
• W2022107795 creator A5022408763 @default.
• W2022107795 creator A5026550581 @default.
• W2022107795 creator A5066222424 @default.
• W2022107795 creator A5080705201 @default.
• W2022107795 creator A5081195905 @default.
• W2022107795 creator A5040409765 @default.
• W2022107795 date "2007-02-01" @default.
• W2022107795 modified "2023-09-27" @default.
• W2022107795 title "The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge" @default.
• W2022107795 cites W1517359188 @default.
• W2022107795 cites W1977404509 @default.
• W2022107795 cites W1982886115 @default.
• W2022107795 cites W1993829790 @default.
• W2022107795 cites W1996696073 @default.
• W2022107795 cites W2000587334 @default.
• W2022107795 cites W2005698822 @default.
• W2022107795 cites W2021794240 @default.
• W2022107795 cites W2037439352 @default.
• W2022107795 cites W2038167979 @default.
• W2022107795 cites W2040514575 @default.
• W2022107795 cites W2040634115 @default.
• W2022107795 cites W2042007683 @default.
• W2022107795 cites W2053758625 @default.
• W2022107795 cites W2077134619 @default.
• W2022107795 cites W2080529843 @default.
• W2022107795 cites W2092396047 @default.
• W2022107795 cites W2099652899 @default.
• W2022107795 cites W2101274167 @default.
• W2022107795 cites W2110658984 @default.
• W2022107795 cites W2117903527 @default.
• W2022107795 cites W2120547874 @default.
• W2022107795 cites W2121464855 @default.
• W2022107795 cites W2121491142 @default.
• W2022107795 cites W2125252801 @default.
• W2022107795 cites W2128177638 @default.
• W2022107795 cites W2134395184 @default.
• W2022107795 cites W2157910210 @default.
• W2022107795 cites W4211171942 @default.
• W2022107795 doi "https://doi.org/10.1016/j.jaci.2006.10.018" @default.
• W2022107795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17141859" @default.
• W2022107795 hasPublicationYear "2007" @default.
• W2022107795 type Work @default.
• W2022107795 sameAs 2022107795 @default.
• W2022107795 citedByCount "38" @default.
• W2022107795 countsByYear W20221077952012 @default.
• W2022107795 countsByYear W20221077952013 @default.
• W2022107795 countsByYear W20221077952014 @default.
• W2022107795 countsByYear W20221077952015 @default.
• W2022107795 countsByYear W20221077952016 @default.
• W2022107795 countsByYear W20221077952019 @default.
• W2022107795 countsByYear W20221077952021 @default.
• W2022107795 crossrefType "journal-article" @default.
• W2022107795 hasAuthorship W2022107795A5011563899 @default.
• W2022107795 hasAuthorship W2022107795A5015743774 @default.
• W2022107795 hasAuthorship W2022107795A5018374796 @default.
• W2022107795 hasAuthorship W2022107795A5022408763 @default.
• W2022107795 hasAuthorship W2022107795A5026550581 @default.
• W2022107795 hasAuthorship W2022107795A5040409765 @default.
• W2022107795 hasAuthorship W2022107795A5066222424 @default.
• W2022107795 hasAuthorship W2022107795A5080705201 @default.
• W2022107795 hasAuthorship W2022107795A5081195905 @default.
• W2022107795 hasBestOaLocation W20221077951 @default.
• W2022107795 hasConcept C126322002 @default.
• W2022107795 hasConcept C2776042228 @default.
• W2022107795 hasConcept C2776136866 @default.
• W2022107795 hasConcept C2776178081 @default.
• W2022107795 hasConcept C2776954882 @default.
• W2022107795 hasConcept C2777714996 @default.
• W2022107795 hasConcept C2779871671 @default.
• W2022107795 hasConcept C2780252434 @default.
• W2022107795 hasConcept C2780769369 @default.
• W2022107795 hasConcept C2781018748 @default.
• W2022107795 hasConcept C2781142857 @default.
• W2022107795 hasConcept C2781260171 @default.
• W2022107795 hasConcept C42219234 @default.
• W2022107795 hasConcept C71924100 @default.
• W2022107795 hasConcept C98274493 @default.
• W2022107795 hasConceptScore W2022107795C126322002 @default.
• W2022107795 hasConceptScore W2022107795C2776042228 @default.
• W2022107795 hasConceptScore W2022107795C2776136866 @default.
• W2022107795 hasConceptScore W2022107795C2776178081 @default.
• W2022107795 hasConceptScore W2022107795C2776954882 @default.
• W2022107795 hasConceptScore W2022107795C2777714996 @default.
• W2022107795 hasConceptScore W2022107795C2779871671 @default.
• W2022107795 hasConceptScore W2022107795C2780252434 @default.
• W2022107795 hasConceptScore W2022107795C2780769369 @default.
• W2022107795 hasConceptScore W2022107795C2781018748 @default.
• W2022107795 hasConceptScore W2022107795C2781142857 @default.
• W2022107795 hasConceptScore W2022107795C2781260171 @default.
• W2022107795 hasConceptScore W2022107795C42219234 @default.
• W2022107795 hasConceptScore W2022107795C71924100 @default.
• W2022107795 hasConceptScore W2022107795C98274493 @default.
• W2022107795 hasFunder F4320307770 @default.

• next